TRENDS IN VOLUMES OF ADULT AND PAEDIATRIC ARV FORMULATIONS IN LMICS. PRELIMINARY ANALYSIS FROM THE GPRM DATA

Boniface Dongmo-Nguimfack

WHO/HIV/SIP



Denominator used for calculation: Years and number of patient-years

Years	2011	2012	2013	2014	2015
Thousands API Years	16,970	22,391	28,761	29,287	27,074
Thousands Patient Years	5,657	7,464	9,587	9,762	9,025




Data included

- CHAI/UNITAID:
 - Data included up to 09.2014
- GFATM
 - PQR data included up to 31.
 12.2015 but 2015 not complete given reporting delays in PQR
- SCMS
 - Data included up to 31.12.2015
- Rest of PEPFAR
 - Data included up to 12.2013

- UNICEF
 - Data included up to 31.12.2015
- IDA:
 - Data included up to 31.12.2015
- MISSIONPHARMA
 - Data included up to 04.2015
- WHOCPS
 - Data included up to 31.12.2015




Market share (% of total volume in PYR of nucleoside reverse transcriptase inhibitors, excluding FTC and 3TC)






Market share (% of total volume in PYR of 3TC and FTC)






Market share (% of total volume in PYR of EFV, NVP and ETV)






Market share (% of total volume in PYR of protease inhibitors, excluding ritonavir)






Relative uptake of tenofovir containing formulations





Relative uptake of zidovudine containing formulations





FORECASTING DEMAND FOR ARVS

TRENDS OF PEDIATRIC FORMULATIONS UPTAKE FROM THE GPRM DATABASE




World Health Organization

Denominator used for calculation: Years and Number of Patient Years

	2011	2012	2013	2014	2015
Thousands API Years	1,119	981	1,513	1,329	552
Thousands Patient Years	373	327	504	443	184




Market share (%) of nucleoside reverse transcriptase inhibitors (excluding 3TC and FTC)



ABC ddi d4T AZT




Relative uptake of abacavir containing formulations






Relative uptake of didanosine formulations






Relative uptake of different zidovudine containing formulations



Organization




Relative uptake of stavudine containing formulations






Relative uptake of different lopinavir formulations





Relative market share of non-nucleoside reverse transcriptase inhibitors plus LPV





Thank you



World Health Organization